Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beclometasone/formoterol/glycopyrronium - Chiesi Farmaceutici

Next Previous
Search
Drug Profile

Beclometasone/formoterol/glycopyrronium - Chiesi Farmaceutici

Alternative Names: Beclometasone dipropionate anhydrous/formoterol fumarate dihydrate/glycopyrronium bromide - Chiesi Farmaceutici; Trydonis

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Developer Chiesi Farmaceutici; Chiesi USA
  • Class Antiasthmatics; Bronchodilators; Chlorinated steroids; Ethanolamines; Pregnadienetriols; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Muscarinic receptor antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase III Asthma

Most Recent Events

  • 24 Feb 2025 Chiesi Farmaceutici completes a phase-III trial in Asthma in Spain, Slovakia, Romania, Poland, Netherlands, Italy, Hungary, Greece, Germany, Czechia, Bulgaria, Armenia, Georgia, Serbia and the UK (Inhalation, Powder) (NCT06264674)
  • 27 Nov 2023 Phase-III clinical trials in Asthma in Bulgaria, Czech Republic, Germany, Greece, Hungary, Italy, Netherlands, Poland, Romania, Slovakia, Spain (Inhalation) (NCT06264674)
  • 13 Nov 2023 Phase-III clinical trials in Asthma in United Kingdom, Serbia, Georgia and Armenia (Inhalation) (ISRCTN17142179) (NCT06264674) (EudraCT2023-503333-22-00)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top